Status:
RECRUITING
Study on c-Met Targeted PET/CT Imaging in NSCLC
Lead Sponsor:
Xilin Sun
Collaborating Sponsors:
Henan Provincial People's Hospital
Conditions:
PET/CT Imaging
NSCLC
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.
Detailed Description
In the study, NSCLC patients with different c-Met activation status (c-Met overexpression, MET exon 14 skipping mutation, MET amplification, MET wild type) confirmed by pathology or gene detection wil...
Eligibility Criteria
Inclusion
- Age range 18-75 years, open to both male and female participants;
- Normal hepatic/renal function and cardiac function;
- Expected survival of at least 12 weeks;
- Good adherence to follow-up;
- Presence of at least one measurable target lesion according to RECIST 1.1 criteria;
- Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;
- Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors;
- Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.
Exclusion
- Severe abnormalities in liver and renal function and blood counts;
- Patients planning to conceive;
- Pregnant or lactating women;
- Individuals unable to lie flat for thirty minutes;
- Individuals who refuse to participate in this clinical study;
- Individuals suffering from claustrophobia or other psychiatric disorders;
- Other situations deemed unsuitable for trial participation by the researchers.
Key Trial Info
Start Date :
October 26 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 28 2025
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT06911697
Start Date
October 26 2023
End Date
June 28 2025
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150028